Free Trial
NASDAQ:GWPH

GW Pharmaceuticals (GWPH) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$218.96
$218.96
50-Day Range
$216.90
$219.28
52-Week Range
$87.07
$219.57
Volume
N/A
Average Volume
899,771 shs
Market Capitalization
$6.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GWPH stock logo

About GW Pharmaceuticals Stock (NASDAQ:GWPH)

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

GWPH Stock News Headlines

GWPRF Historical Data
George Washington University
GW Pharmaceuticals PLC (GWPRF)
GWPH Jan 2023 195.000 put
GW Pharmaceuticals (GWPH): What Awaits in Q1 Earnings?
See More Headlines
Receive GWPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GW Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2020
Today
6/12/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GWPH
Fax
N/A
Employees
1,161
Year Founded
N/A

Profitability

Net Income
$-9,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$311.33 million
Cash Flow
$0.01 per share
Book Value
$23.48 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.86 billion
Optionable
Optionable
Beta
2.15
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives


GWPH Stock Analysis - Frequently Asked Questions

How were GW Pharmaceuticals' earnings last quarter?

GW Pharmaceuticals plc (NASDAQ:GWPH) posted its quarterly earnings data on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.27. The biopharmaceutical company earned $137.10 million during the quarter, compared to analyst estimates of $97.66 million. GW Pharmaceuticals had a negative net margin of 11.05% and a negative trailing twelve-month return on equity of 7.46%. The company's revenue was up 50.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.04) earnings per share.

What is Justin Gover's approval rating as GW Pharmaceuticals' CEO?

14 employees have rated GW Pharmaceuticals Chief Executive Officer Justin Gover on Glassdoor.com. Justin Gover has an approval rating of 80% among the company's employees.

What other stocks do shareholders of GW Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Intel (INTC), Netflix (NFLX), Gilead Sciences (GILD), Advanced Micro Devices (AMD).

This page (NASDAQ:GWPH) was last updated on 6/12/2024 by MarketBeat.com Staff

From Our Partners